Diabetic Macular Edema

An oral therapy for aged-related macular degeneration could be on the horizon after displaying efficacy in a recent phase 2 study.

Carl Regillo, MD, who presented 96-week data of brolucizumab at ASRS 2019, discusses how brolucizumab could impact care of wAMD in a real-world setting.

More patients undergoing long-term use anti-VEGF therapy saw improvements in visual acuity than saw declines after 10 years.

Investigators from Wills Eye and Retina Consultants of Austin presented 96-week data from the HAWK and HARRIER trials at ASRS 2019.

Peter Kaiser, MD, presented data from a phase 2 trial examining the safety and efficacy of risuteganib at ASRS 2019.

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Kodiak's KSI-301 was shown to have sustained benefit and safety in a phase 1a study involving patients with severe DME.

Older patients could benefit from skipping traditional bedrest in favor of an exercise program when hospitalized with an acute illness.

Analysis of 2 phase 3 trials found that 24% of patients experienced new choroidal neovascularization over the course of the 96-week trials.

An analysis of more than 650 eyes find that optical coherence tomography central subfield thickness accounts for only a small proportion of total variation in changes in visual acuity.

Investigators examined anti-VEGF injections claims data among Medicare Part B beneficiaries from 2012 to 2015 and found that aflibercept injections increased by 69% during that time.

A recent study reviewed operating times of ophthalmic procedures before and after transition to a new EHR system in 2 outpatient departments and an ambulatory surgical center.

Ranibizumab was approved for AMD treatment in Korea in 2007, but most supporting trials had been conducted among Caucasian patients.

A review highlights aflibercept’s efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

Metformin use associated with a 58% reduced risk of age-related macular degeneration (AMD) in a case-controlled retrospective study.

Aflibercept (Eylea) is an anti-VEGF treatment administered as an intravitreal injection.

Results from the 3-year European Iluvien Registry Safety Study that examined outcomes of the fluocinolone acetonide implant compared to those of the pivotal FAME trials.

Patients who experienced hypertensive disorders in pregnancy were 80% more likely to develop choroidal neovascular AMD at an early age.

An early-start treat-and-extend regimen produced comparable efficacy with fewer aflibercept injections than regular injections every 8 weeks.

People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.

The ZEBRA study found that ziv-aflibercept was non-inferior to aflibercept and ranibizumab, and was more cost-effective.

The field has a growing demand of care, and dropping rate of new specialists. The solution can start at medical schools.

Investigator Lim sees hope that the EyeArt AI system will be able to screen more patients for diabetic retinopathy and help prevent blindness.

The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.

After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.